Do analysts rate MRAI or AIRS?

AirSculpt Technologies has a consensus price target of $4.50, suggesting a potential upside of 64.23%. Given AirSculpt Technologies' stronger consensus rating and higher probable upside, analysts plainly believe AirSculpt Technologies is more favorable than Marpai. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Marpai 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 AirSculpt Technologies 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50

Does the media favor MRAI or AIRS?

In the previous week, AirSculpt Technologies had 3 more articles in the media than Marpai. MarketBeat recorded 4 mentions for AirSculpt Technologies and 1 mentions for Marpai. AirSculpt Technologies' average media sentiment score of 1.32 beat Marpai's score of 0.95 indicating that AirSculpt Technologies is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Marpai 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive AirSculpt Technologies 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts rate MRAI or XGN?

Exagen has a consensus target price of $9.63, suggesting a potential upside of 21.53%. Given Exagen's stronger consensus rating and higher possible upside, analysts clearly believe Exagen is more favorable than Marpai. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Marpai 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Exagen 1 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 2.89

Which has preferable earnings and valuation, MRAI or XGN?

Exagen has higher revenue and earnings than Marpai. Exagen is trading at a lower price-to-earnings ratio than Marpai, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Marpai $34.87M 1.80 -$28.75M -$0.77 N/A Exagen $66.57M 2.88 -$19.95M -$0.81 N/A

Is MRAI or XGN more profitable?

Exagen has a net margin of -26.61% compared to Marpai's net margin of -85.70%. Marpai's return on equity of 0.00% beat Exagen's return on equity. Company Net Margins Return on Equity Return on Assets Marpai -85.70% N/A -100.23% Exagen -26.61% -104.46% -28.93%

Does the media favor MRAI or XGN?

In the previous week, Exagen had 1 more articles in the media than Marpai. MarketBeat recorded 2 mentions for Exagen and 1 mentions for Marpai. Exagen's average media sentiment score of 1.76 beat Marpai's score of 0.95 indicating that Exagen is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Marpai 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Exagen 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Do analysts prefer LFMD or MRAI?

LifeMD presently has a consensus price target of $7.57, suggesting a potential upside of 128.74%. Given LifeMD's stronger consensus rating and higher probable upside, analysts clearly believe LifeMD is more favorable than Marpai. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score LifeMD 1 Sell rating(s) 1 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 2.70 Marpai 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has better valuation & earnings, LFMD or MRAI?

LifeMD has higher revenue and earnings than Marpai. LifeMD is trading at a lower price-to-earnings ratio than Marpai, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio LifeMD $194.05M 0.82 $14.35M -$0.05 N/A Marpai $34.87M 1.80 -$28.75M -$0.77 N/A

Is LFMD or MRAI more profitable?

LifeMD has a net margin of 0.10% compared to Marpai's net margin of -85.70%. Marpai's return on equity of 0.00% beat LifeMD's return on equity. Company Net Margins Return on Equity Return on Assets LifeMD 0.10% -168.23% -31.27% Marpai -85.70% N/A -100.23%

Does the media refer more to LFMD or MRAI?

In the previous week, LifeMD had 2 more articles in the media than Marpai. MarketBeat recorded 3 mentions for LifeMD and 1 mentions for Marpai. Marpai's average media sentiment score of 0.95 beat LifeMD's score of 0.69 indicating that Marpai is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment LifeMD 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Marpai 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts rate MRAI or JYNT?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Marpai 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Joint 1 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.67

Which has better earnings & valuation, MRAI or JYNT?

Joint has higher revenue and earnings than Marpai. Marpai is trading at a lower price-to-earnings ratio than Joint, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Marpai $34.87M 1.80 -$28.75M -$0.77 N/A Joint $54.90M 2.17 $2.91M $0.27 31.26

Is MRAI or JYNT more profitable?

Joint has a net margin of 6.49% compared to Marpai's net margin of -85.70%. Joint's return on equity of 12.02% beat Marpai's return on equity. Company Net Margins Return on Equity Return on Assets Marpai -85.70% N/A -100.23% Joint 6.49% 12.02% 3.47%

Which has better valuation & earnings, MRAI or CO?

Global Cord Blood has higher revenue and earnings than Marpai. Marpai is trading at a lower price-to-earnings ratio than Global Cord Blood, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Marpai $34.87M 1.80 -$28.75M -$0.77 N/A Global Cord Blood $1.24B 0.09 $79.04M $0.64 1.49

Is MRAI or CO more profitable?

Global Cord Blood has a net margin of 0.00% compared to Marpai's net margin of -85.70%. Company Net Margins Return on Equity Return on Assets Marpai -85.70% N/A -100.23% Global Cord Blood N/A N/A N/A

Marpai (MRAI) Competitors

$2.33 0.00 (0.00%)

As of 08/21/2026 03:52 PM Eastern

Compare

MRAI vs. AIRS, XGN, LFMD, JYNT, and CO

Should you buy Marpai stock or one of its competitors? Marpai's main competitors and comparable companies include AirSculpt Technologies (AIRS), Exagen (XGN), LifeMD (LFMD), Joint (JYNT), and Global Cord Blood (CO). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare providers & services" industry.

How does Marpai compare to AirSculpt Technologies?

Marpai (NASDAQ:MRAI) and AirSculpt Technologies (NASDAQ:AIRS) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, media sentiment, dividends, earnings, risk, analyst recommendations, valuation and institutional ownership.

Marpai has a beta of 4.74, suggesting that its stock price is 374% more volatile than the broader market. Comparatively, AirSculpt Technologies has a beta of 2.33, suggesting that its stock price is 133% more volatile than the broader market.

AirSculpt Technologies has a net margin of -7.79% compared to Marpai's net margin of -85.70%. Marpai's return on equity of 0.00% beat AirSculpt Technologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Marpai	-85.70%	N/A	-100.23%
AirSculpt Technologies	-7.79%	-5.83%	-2.88%

AirSculpt Technologies has higher revenue and earnings than Marpai. AirSculpt Technologies is trading at a lower price-to-earnings ratio than Marpai, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Marpai	$34.87M	1.80	-$28.75M	-$0.77	N/A
AirSculpt Technologies	$151.82M	1.30	-$11.67M	-$0.18	N/A

49.8% of Marpai shares are held by institutional investors. Comparatively, 91.5% of AirSculpt Technologies shares are held by institutional investors. 46.1% of Marpai shares are held by insiders. Comparatively, 44.6% of AirSculpt Technologies shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

In the previous week, AirSculpt Technologies had 3 more articles in the media than Marpai. MarketBeat recorded 4 mentions for AirSculpt Technologies and 1 mentions for Marpai. AirSculpt Technologies' average media sentiment score of 1.32 beat Marpai's score of 0.95 indicating that AirSculpt Technologies is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Marpai	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
AirSculpt Technologies	3 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

AirSculpt Technologies has a consensus price target of $4.50, suggesting a potential upside of 64.23%. Given AirSculpt Technologies' stronger consensus rating and higher probable upside, analysts plainly believe AirSculpt Technologies is more favorable than Marpai.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Marpai	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
AirSculpt Technologies	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

Summary

AirSculpt Technologies beats Marpai on 10 of the 15 factors compared between the two stocks.

How does Marpai compare to Exagen?

Marpai (NASDAQ:MRAI) and Exagen (NASDAQ:XGN) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their profitability, valuation, dividends, earnings, risk, media sentiment, analyst recommendations and institutional ownership.

Exagen has a net margin of -26.61% compared to Marpai's net margin of -85.70%. Marpai's return on equity of 0.00% beat Exagen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Marpai	-85.70%	N/A	-100.23%
Exagen	-26.61%	-104.46%	-28.93%

Exagen has a consensus target price of $9.63, suggesting a potential upside of 21.53%. Given Exagen's stronger consensus rating and higher possible upside, analysts clearly believe Exagen is more favorable than Marpai.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Marpai	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Exagen	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.89

Exagen has higher revenue and earnings than Marpai. Exagen is trading at a lower price-to-earnings ratio than Marpai, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Marpai	$34.87M	1.80	-$28.75M	-$0.77	N/A
Exagen	$66.57M	2.88	-$19.95M	-$0.81	N/A

49.8% of Marpai shares are held by institutional investors. Comparatively, 75.3% of Exagen shares are held by institutional investors. 46.1% of Marpai shares are held by company insiders. Comparatively, 10.4% of Exagen shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Marpai has a beta of 4.74, suggesting that its stock price is 374% more volatile than the broader market. Comparatively, Exagen has a beta of 2.05, suggesting that its stock price is 105% more volatile than the broader market.

In the previous week, Exagen had 1 more articles in the media than Marpai. MarketBeat recorded 2 mentions for Exagen and 1 mentions for Marpai. Exagen's average media sentiment score of 1.76 beat Marpai's score of 0.95 indicating that Exagen is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Marpai	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Exagen	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Summary

Exagen beats Marpai on 12 of the 17 factors compared between the two stocks.

How does Marpai compare to LifeMD?

LifeMD (NASDAQ:LFMD) and Marpai (NASDAQ:MRAI) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, dividends, media sentiment, valuation, profitability, institutional ownership, risk and analyst recommendations.

In the previous week, LifeMD had 2 more articles in the media than Marpai. MarketBeat recorded 3 mentions for LifeMD and 1 mentions for Marpai. Marpai's average media sentiment score of 0.95 beat LifeMD's score of 0.69 indicating that Marpai is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
LifeMD	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Marpai	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

35.5% of LifeMD shares are owned by institutional investors. Comparatively, 49.8% of Marpai shares are owned by institutional investors. 17.2% of LifeMD shares are owned by company insiders. Comparatively, 46.1% of Marpai shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

LifeMD presently has a consensus price target of $7.57, suggesting a potential upside of 128.74%. Given LifeMD's stronger consensus rating and higher probable upside, analysts clearly believe LifeMD is more favorable than Marpai.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
LifeMD	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.70
Marpai	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

LifeMD has a beta of 2.02, indicating that its stock price is 102% more volatile than the broader market. Comparatively, Marpai has a beta of 4.74, indicating that its stock price is 374% more volatile than the broader market.

LifeMD has a net margin of 0.10% compared to Marpai's net margin of -85.70%. Marpai's return on equity of 0.00% beat LifeMD's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
LifeMD	0.10%	-168.23%	-31.27%
Marpai	-85.70%	N/A	-100.23%

LifeMD has higher revenue and earnings than Marpai. LifeMD is trading at a lower price-to-earnings ratio than Marpai, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
LifeMD	$194.05M	0.82	$14.35M	-$0.05	N/A
Marpai	$34.87M	1.80	-$28.75M	-$0.77	N/A

Summary

LifeMD beats Marpai on 9 of the 16 factors compared between the two stocks.

How does Marpai compare to Joint?

Marpai (NASDAQ:MRAI) and Joint (NASDAQ:JYNT) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, risk, earnings, valuation, media sentiment, analyst recommendations, institutional ownership and profitability.

Marpai has a beta of 4.74, suggesting that its share price is 374% more volatile than the broader market. Comparatively, Joint has a beta of 1.1, suggesting that its share price is 10% more volatile than the broader market.

Joint has a net margin of 6.49% compared to Marpai's net margin of -85.70%. Joint's return on equity of 12.02% beat Marpai's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Marpai	-85.70%	N/A	-100.23%
Joint	6.49%	12.02%	3.47%

49.8% of Marpai shares are held by institutional investors. Comparatively, 76.9% of Joint shares are held by institutional investors. 46.1% of Marpai shares are held by insiders. Comparatively, 30.2% of Joint shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Marpai	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Joint	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67

In the previous week, Marpai had 1 more articles in the media than Joint. MarketBeat recorded 1 mentions for Marpai and 0 mentions for Joint. Marpai's average media sentiment score of 0.95 beat Joint's score of -0.28 indicating that Marpai is being referred to more favorably in the media.

Company	Overall Sentiment
Marpai	Positive
Joint	Neutral

Joint has higher revenue and earnings than Marpai. Marpai is trading at a lower price-to-earnings ratio than Joint, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Marpai	$34.87M	1.80	-$28.75M	-$0.77	N/A
Joint	$54.90M	2.17	$2.91M	$0.27	31.26

Summary

Joint beats Marpai on 10 of the 14 factors compared between the two stocks.

How does Marpai compare to Global Cord Blood?

Marpai (NASDAQ:MRAI) and Global Cord Blood (NYSE:CO) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their risk, earnings, profitability, dividends, analyst recommendations, valuation, media sentiment and institutional ownership.

Marpai has a beta of 4.74, indicating that its stock price is 374% more volatile than the broader market. Comparatively, Global Cord Blood has a beta of 0.16, indicating that its stock price is 84% less volatile than the broader market.

In the previous week, Marpai had 1 more articles in the media than Global Cord Blood. MarketBeat recorded 1 mentions for Marpai and 0 mentions for Global Cord Blood. Marpai's average media sentiment score of 0.95 beat Global Cord Blood's score of 0.00 indicating that Marpai is being referred to more favorably in the media.

Company	Overall Sentiment
Marpai	Positive
Global Cord Blood	Neutral

Global Cord Blood has higher revenue and earnings than Marpai. Marpai is trading at a lower price-to-earnings ratio than Global Cord Blood, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Marpai	$34.87M	1.80	-$28.75M	-$0.77	N/A
Global Cord Blood	$1.24B	0.09	$79.04M	$0.64	1.49

Global Cord Blood has a net margin of 0.00% compared to Marpai's net margin of -85.70%.

Company	Net Margins	Return on Equity	Return on Assets
Marpai	-85.70%	N/A	-100.23%
Global Cord Blood	N/A	N/A	N/A

49.8% of Marpai shares are held by institutional investors. 46.1% of Marpai shares are held by insiders. Comparatively, 0.5% of Global Cord Blood shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

Marpai and Global Cord Blood tied by winning 6 of the 12 factors compared between the two stocks.

Get Marpai News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MRAI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

MRAI vs. The Competition

Export

Metric	Marpai	Healthcare Providers & Services Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$62.61M	$9.83B	$7.37B	$12.83B
Dividend Yield	N/A	2.55%	2.53%	10.78%
P/E Ratio	-0.88	34.38	272.33	24.21
Price / Sales	1.80	4.98	613.18	90.27
Price / Cash	N/A	24.64	29.03	36.90
Price / Book	-1.35	5.40	11.25	6.42
Net Income	-$28.75M	$309.96M	$3.47B	$348.89M
7 Day Performance	4.48%	0.99%	2.33%	0.57%
1 Month Performance	-1.69%	2.30%	7.72%	4.90%
1 Year Performance	70.07%	15.69%	25.22%	17.06%

Marpai Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
MRAI Marpai	N/A	$2.33 flat	N/A	+70.1%	$62.61M	$34.87M	N/A	150	High Trading Volume
AIRS AirSculpt Technologies	2.5273 of 5 stars	$2.81 +4.5%	$4.50 +60.1%	-57.8%	$194.30M	$151.82M	N/A	240
XGN Exagen	3.8325 of 5 stars	$7.43 +12.7%	$9.63 +29.5%	-21.6%	$159.65M	$66.57M	N/A	220	Positive News
LFMD LifeMD	2.7666 of 5 stars	$3.40 +4.0%	$7.57 +122.7%	-47.7%	$157.62M	$194.05M	N/A	230
JYNT Joint	1.8705 of 5 stars	$8.23 -3.6%	N/A	-20.5%	$116.40M	$58.55M	30.48	320

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:MRAI) was last updated on 8/24/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Marpai (MRAI) Competitors

MRAI vs. AIRS, XGN, LFMD, JYNT, and CO

How does Marpai compare to AirSculpt Technologies?

Summary

How does Marpai compare to Exagen?

Summary

How does Marpai compare to LifeMD?

Summary

How does Marpai compare to Joint?

Summary

How does Marpai compare to Global Cord Blood?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MRAI vs. The Competition

Marpai Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Marpai (MRAI) Competitors

MRAI vs. AIRS, XGN, LFMD, JYNT, and CO

How does Marpai compare to AirSculpt Technologies?

Which has more risk and volatility, MRAI or AIRS?

Is MRAI or AIRS more profitable?

Which has better valuation & earnings, MRAI or AIRS?

Do insiders and institutionals have more ownership in MRAI or AIRS?

Does the media favor MRAI or AIRS?

Do analysts rate MRAI or AIRS?

Summary

How does Marpai compare to Exagen?

Is MRAI or XGN more profitable?

Do analysts rate MRAI or XGN?

Which has preferable earnings and valuation, MRAI or XGN?

Do insiders & institutionals have more ownership in MRAI or XGN?

Which has more volatility and risk, MRAI or XGN?

Does the media favor MRAI or XGN?

Summary

How does Marpai compare to LifeMD?

Does the media refer more to LFMD or MRAI?

Do institutionals and insiders hold more shares of LFMD or MRAI?

Do analysts prefer LFMD or MRAI?

Which has more volatility and risk, LFMD or MRAI?

Is LFMD or MRAI more profitable?

Which has better valuation & earnings, LFMD or MRAI?

Summary

How does Marpai compare to Joint?

Which has more risk and volatility, MRAI or JYNT?

Is MRAI or JYNT more profitable?

Do institutionals & insiders have more ownership in MRAI or JYNT?

Do analysts rate MRAI or JYNT?

Does the media refer more to MRAI or JYNT?

Which has better earnings & valuation, MRAI or JYNT?

Summary

How does Marpai compare to Global Cord Blood?

Which has more volatility and risk, MRAI or CO?

Does the media refer more to MRAI or CO?

Which has better valuation & earnings, MRAI or CO?

Is MRAI or CO more profitable?

Do insiders & institutionals hold more shares of MRAI or CO?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MRAI vs. The Competition

Marpai Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools